Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Federal Reserve shifts to quarter-point rate rise but warns of more to come
    • ECB set to raise rates despite fall in eurozone inflation
    • ‘Hybrid identities’: why Germany is updating its citizenship rules
    • Italy to join forces with France in supplying air defences to Ukraine
    • Czech president-elect says west must accept China is ‘not friendly’
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • Adani Enterprises calls off $2.4bn share sale
      • ‘Extreme leverage’? Adani’s debt-driven expansion under scrutiny
      • Adani sell-off tops $90bn as share sale fails to ease crisis
      • Gautam Adani defends ‘robust’ business as stock losses reach $100bn
      • How First Abu Dhabi Bank pursued Standard Chartered and ‘opened Pandora’s box’
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Adani Enterprises calls off $2.4bn share sale
      • Live news updates from February 1: Fed lifts rates 0.25 points, Eurozone inflation slows sharply
      • US stocks jump after Fed announces smaller rate rise
      • Shell profits more than double to record $40bn
      • Lebanon devalues official exchange rate by 90%
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
      Most Read
      • The return of the ‘British disease’
      • End the Fed ‘put’
      • Beware the great battery industry fallacy
      • Conservatives are forced to face the economic case for net zero
      • The corporate world is losing its grip on cyber risk
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Shoshana Zuboff: ‘Privacy has been extinguished. It is now a zombie’
      • A new generation refuses to keep quiet on age discrimination at work
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Alexa Chung on the unpolished appeal of Indie Sleaze
      • The secrets of the Mercedes-Benz Holy Halls
      • Why I’m only buying five new things in 2023
      • What a perilous flight from North Korea tells us about digital connections
      • Annie Morris and Idris Khan’s guide to West Sussex
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Oxford Nanopore Technologies

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 8 November, 2021
      Healthcare
      Pandemic puts Oxford Nanopore ‘on the map’

      University spinout’s portable DNA sequencer has proved invaluable in tracking the global spread of coronavirus

    • Thursday, 30 September, 2021
      Oxford Nanopore shares surge more than 40 per cent in London IPO

      UK genomics group makes devices used to sequence Covid variants

    • Monday, 13 September, 2021
      Lex
      Oxford Nanopore/IPO: sequencing a would-be British success story Premium content

      Genomics company’s float should have no problems getting off the ground

    • Thursday, 9 September, 2021
      Oxford Nanopore to launch IPO in London after Covid-19 success

      Genomics company gained global prominence with role in helping track coronavirus

    • Friday, 2 July, 2021
      Oxford Nanopore to use ‘anti-takeover’ shares to remain British champion

      DNA sequencing start-up wants to avoid being bought by foreign competitor after IPO

    • Tuesday, 4 May, 2021
      Lex
      Oxford Nanopore/IPO: sequencer has Woodford in its DNA Premium content

      Investors should focus on the science, setting aside market froth

    • Tuesday, 30 March, 2021
      Oxford Nanopore picks London for latest tech IPO

      DNA sequencing group expected to be valued at £4bn to £7bn in one of largest UK floats this year

    • Friday, 11 December, 2020
      UK business & economy
      Senior England Test and Trace official joins supplier weeks after leaving post

      Emma Stanton starts at Oxford Nanopore after contract ends at government programme

    • Tuesday, 13 October, 2020
      LombardKate Burgess
      Last orders loom for big indebted pub groups

      National inn chains suffer as new lockdown policy heralds more pub closures

    • Sunday, 16 February, 2020
      News in-depthTechnology sector
      Why UK university spinouts are courting overseas investors

      There are plenty of discoveries to bring to market but domestic funding has been squeezed

    • Sunday, 7 July, 2019
      Biotech
      Oxford Nanopore opens DNA decoding kit factory

      UK biotech company hopes to challenge US dominance of gene sequencing market

    • Wednesday, 3 April, 2019
      Biotech
      Oxford Nanopore’s flotation plans are a boon for Neil Woodford

      Gene analysis group’s decision to list helps fund manager remain compliant with regulations

    • Thursday, 18 October, 2018
      Science
      Amgen invests £50m in gene-reading company Oxford Nanopore

      California-based group acquires 3 per cent stake in UK sequencing company

    • Tuesday, 20 March, 2018
      UK inward investment
      Oxford Nanopore value reaches £1.5bn as it taps Asia-Pacific funding

      Fast-growing UK biotech will build factory to meet demand for gene sequencing machines

    • Tuesday, 23 May, 2017
      LexTechnology sector
      IP Group/Touchstone: varsity match Premium content

      No laughing matter for minority investors

    • Wednesday, 5 April, 2017
      Special ReportTomorrow’s Global Business: Raising Capital
      Testing times for the UK’s university spin-off funds

      Investing in intellectual property commercialisation is not without risks

    • Monday, 12 December, 2016
      LombardJonathan Guthrie
      Sky: Gilbert must make Fox talk turkey

      Independent directors should back a scheme of arrangement for benefit of investors

    • Monday, 12 December, 2016
      UK companies
      UK biotech group raises £100m to sell DNA-reading tools in Asia

      Oxford Nanopore announces new funding from Woodford Investment and HK-based investor

    • Monday, 12 December, 2016
      Technology sector
      Oxford Nanopore announces £100m fundraising
    • Thursday, 3 November, 2016
      UK companies
      Woodford-backed UK biotech group faces new legal challenge

      Oxford Nanopore received complaint over patent infringement of two-strand DNA sequencing

    • Thursday, 4 August, 2016
      LombardInsurance
      Neil Woodford’s patient trust feeling poorly

      About 40% of WPC is in unquoted companies and two-thirds in healthcare

    • Friday, 1 April, 2016
      Pharmaceuticals sector
      Whole-genome breakthrough promises tonic for healthcare

      Accurately sequencing an individual’s DNA for less than $1,000 is now possible

    • Tuesday, 1 September, 2015
      Technology sector
      Genes genie: Oxford Nanopore’s Gordon Sanghera

      The British scientist behind a pioneering DNA sequencer is plotting its international success

    • Tuesday, 21 July, 2015
      LombardKate Burgess
      UK biotechs dive into a deepening pool

      Start-ups tap homegrown capital rather than going stateside

    • Tuesday, 21 July, 2015
      Pharmaceuticals sector
      Record fundraising bolster UK’s biotech challengers
    Previous page You are on page 1 Next page

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition
    • Top sections
    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • The Big Read
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports
    • FT recommends
    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In